| Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture LJ Dickmann, SK Patel, DA Rock, LC Wienkers, JG Slatter Drug Metabolism and Disposition 39 (8), 1415-1422, 2011 | 201 | 2011 |
| Alternative splicing determines the function of CYP4F3 by switching substrate specificity P Christmas, JP Jones, CJ Patten, DA Rock, Y Zheng, SM Cheng, ... Journal of Biological Chemistry 276 (41), 38166-38172, 2001 | 170 | 2001 |
| CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles V Kumar, JL Wahlstrom, DA Rock, CJ Warren, LA Gorman, TS Tracy Drug metabolism and disposition 34 (12), 1966-1975, 2006 | 160 | 2006 |
| Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation RS Foti, DA Rock, LC Wienkers, JL Wahlstrom Drug Metabolism and Disposition 38 (6), 981-987, 2010 | 136 | 2010 |
| SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm KJ Hamblett, AP Jacob, JL Gurgel, ME Tometsko, BM Rock, SK Patel, ... Cancer research 75 (24), 5329-5340, 2015 | 129 | 2015 |
| Time-Dependent Inactivation of P450 3A4 by Raloxifene: Identification of Cys239 as the Site of Apoprotein Alkylation1 BR Baer, LC Wienkers, DA Rock Chemical research in toxicology 20 (6), 954-964, 2007 | 98 | 2007 |
| Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4 BM Rock, SM Hengel, DA Rock, LC Wienkers, KL Kunze Molecular pharmacology 86 (6), 665-674, 2014 | 97 | 2014 |
| Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition BM VandenBrink, RS Foti, DA Rock, LC Wienkers, JL Wahlstrom Drug Metabolism and Disposition 40 (1), 47-53, 2012 | 92 | 2012 |
| Intact mass analysis of monoclonal antibodies by capillary electrophoresis—Mass spectrometry M Han, BM Rock, JT Pearson, DA Rock Journal of Chromatography B 1011, 24-32, 2016 | 88 | 2016 |
| Current approaches for absorption, distribution, metabolism, and excretion characterization of antibody-drug conjugates: an industry white paper E Kraynov, AV Kamath, M Walles, E Tarcsa, A Deslandes, RA Iyer, ... Drug Metabolism and Disposition 44 (5), 617-623, 2016 | 86 | 2016 |
| Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate BM VandenBrink, RS Foti, DA Rock, LC Wienkers, JL Wahlstrom Drug metabolism and disposition 39 (9), 1546-1554, 2011 | 81 | 2011 |
| Enzyme source effects on CYP2C9 kinetics and inhibition V Kumar, DA Rock, CJ Warren, TS Tracy, JL Wahlstrom Drug metabolism and disposition 34 (11), 1903-1908, 2006 | 69 | 2006 |
| Kinetic isotope effects implicate the iron− oxene as the sole oxidant in P450-catalyzed N-dealkylation TS Dowers, DA Rock, DA Rock, JP Jones Journal of the American Chemical Society 126 (29), 8868-8869, 2004 | 69 | 2004 |
| Small molecule quantification by liquid chromatography-mass spectrometry for metabolites of drugs and drug candidates UP Dahal, JP Jones, JA Davis, DA Rock Drug metabolism and disposition 39 (12), 2355-2360, 2011 | 68 | 2011 |
| Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors H Suzuki, MB Kneller, DA Rock, JP Jones, WF Trager, AE Rettie Archives of biochemistry and biophysics 429 (1), 1-15, 2004 | 67 | 2004 |
| Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates JT Pearson, JL Wahlstrom, LJ Dickmann, S Kumar, JR Halpert, ... Chemical research in toxicology 20 (12), 1778-1786, 2007 | 62 | 2007 |
| Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements RS Foti, LJ Dickmann, JA Davis, RJ Greene, JJ Hill, ML Howard, ... Xenobiotica 38 (3), 264-280, 2008 | 61 | 2008 |
| CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9. 3 variant MA Hummel, CW Locuson, PM Gannett, DA Rock, CM Mosher, AE Rettie, ... Molecular pharmacology 68 (3), 644-651, 2005 | 53 | 2005 |
| Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction RS Foti, DA Rock, JT Pearson, JL Wahlstrom, LC Wienkers Drug metabolism and disposition 39 (7), 1188-1195, 2011 | 51 | 2011 |
| Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution KP Conner, BM Rock, GK Kwon, JP Balthasar, L Abuqayyas, LC Wienkers, ... Drug Metabolism and Disposition 42 (11), 1906-1913, 2014 | 50 | 2014 |
